Ultime notizie per Eagle Pharmaceuticals (OTC:EGRX) Azioni

Eagle Pharmaceuticals

Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration.

EAGLE PHARMS INC by Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals Inc

<h3>Gainers</h3>
<ul>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) stock rose 31.0% to $0.46 during Wednesday's after-market session. The company's market cap stands at $9.6 million. </li>
<li>Processa Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares rose 30.07% to $1.73. The market value of their outstanding shares is at $5.6 million. </li>
<li>China Pharma Holdings, Inc. Common Stock (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) stock rose 8.83% to $0.28. </li>
<li>Eagle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGRX#NASDAQ">EGRX</a>) shares increased by 7.94% to $2.31. The market value of their outstanding shares is at $29.9 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) stock moved upwards by 7.89% to $1.64. The company's market cap stands at $2.9 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares increased by 7.36% to $0.1. The market value of their outstanding shares is at $9.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) stock declined by 8.6% to $4.45 during Wednesday's after-market session. The company's market cap stands at $10.1 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares fell 6.34% to $0.28. The company's market cap stands at $2.1 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) stock decreased by 5.3% to $1.25. The company's market cap stands at $16.0 million. </li>
<li>Gossamer Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOSS#NASDAQ">GOSS</a>) stock declined by 4.77% to $1.0. The market value of their outstanding shares is at $226.2 million. </li>
<li>Fractyl Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GUTS#NASDAQ">GUTS</a>) shares fell 4.75% to $2.21. The market value of their outstanding shares is at $105.9 million. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) shares fell 4.66% to $1.64. The market value of their outstanding shares is at $3.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BBLG

CPHI

CTCX

EGRX

GOSS

GUTS

KAPA

PCSA

SNGX

TNFA

12 Health Care Stocks Moving In Wednesday's After-Market Session

U.S. stocks traded slightly higher toward the end of trading, with the Nasdaq Composite gaining around 0.2% on Wednesday.
The Dow traded up 0.07% to 42,186.44 while the NASDAQ gained 0.24% to 17,952.61. The S&amp;P 500 also rose, gaining, 0.03% to 5,710.22.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/09/41091653/how-to-earn-500-a-month-from-mccormick-stock-ahead-of-q3-earnings">How To Earn $500 A Month From McCormick Stock Ahead Of Q3 Earnings</a>
Leading and Lagging Sectors Information technology shares jumped by 0.6% on Wednesday.
In trading on Wednesday, consumer staples shares dipped by 1%.
Top Headline
ConAgra Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>) reported weaker-than-expected first-quarter results.
ConAgra reported quarterly adjusted earnings per share of 53 cents, missing the analyst consensus of 60 cents. Net sales of $2.79 billion (down 3.8%) missed the street view of $2.84 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Joby Aviation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) shares shot up 25% to $6.02 after the company announced that Toyota will invest an additional $500 million to support the certification and commercial production of the electric air taxi.</li>
<li>Shares of RPM International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) got a boost, surging 7% to $128.37 after the company reported better-than-expected first-quarter adjusted EPS results.</li>
<li>MMTec, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTC#NASDAQ">MTC</a>) shares were also up, gaining 46% to $0.6818. Shares of US-listed Chinese stocks traded higher on continued strength following recent stimulus measures and the start of the National Day Golden Week.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) shares dropped 13% to $242.64 after the company provided update on decline in Stars performance for 2025 and how it will impact quality bonus payments in 2026.</li>
<li>Shares of Eagle Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGRX#NASDAQ">EGRX</a>) were down 34% to $2.35 after the company announced it will be delisted from the Nasdaq.</li>
<li>Aditxt Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) was down, falling 30% to $3.1318. Aditxt recently announced a 1-for-40 reverse stock split.</li>
</ul>
Commodities In commodity news, oil traded up 0.4% to $70.08 while gold traded down 0.7% at $2,672.80.
Silver traded up 0.8% to $31.980 on Wednesday, while copper rose 1.3% to $4.65.
Euro zone
European shares closed mixed today. The eurozone's STOXX 600 rose 0.05%, Germany's DAX fell 0.25% and France's CAC 40 rose 0.05%. Spain's IBEX 35 Index fell 0.55%, while London's FTSE 100 gained 0.17%.
The unemployment rate in the Eurozone came in unchanged from the previous month at 6.4% in August.
Asia Pacific Markets
Asian markets closed mixed on Wednesday, with Japan's Nikkei 225 dipping 2.18% and Hong Kong's Hang Seng Index jumping 6.20%.
Economics
<ul>
<li>Private businesses in the U.S. added 143,000 workers to their payrolls during the month of September compared to a revised 103,000 gain in August and higher than market estimates of 124,000, the ADP said.</li>
<li>The EIA said crude oil inventories in the U.S. climbed by 3.889 million barrels for the week ended Sept. 27, versus market estimates of a 1.3 million decline.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41141190/nike-to-100-here-are-10-top-analyst-forecasts-for-wednesday">Nike To $100? Here Are 10 Top Analyst Forecasts For Wednesday</a></li>
</ul>

Earnings

Equities

News

Eurozone

Commodities

Markets

Trading Ideas

ADTX

JOBY

Crude Oil Edges Higher; ConAgra Posts Downbeat Earnings

<h3>Gainers</h3>
<ul>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock moved upwards by 31.2% to $0.31 during Wednesday's regular session. The market value of their outstanding shares is at $2.3 million. </li>
<li>ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) shares increased by 22.06% to $17.68. The market value of their outstanding shares is at $251.6 million. </li>
<li>I-MAB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMAB#NASDAQ">IMAB</a>) stock moved upwards by 20.9% to $1.48. The company's market cap stands at $119.3 million. </li>
<li>BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) shares moved upwards by 19.36% to $2.06. The market value of their outstanding shares is at $99.8 million. </li>
<li>Clover Health Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) stock moved upwards by 17.3% to $3.26. The market value of their outstanding shares is at $1.6 billion. </li>
<li>RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) stock rose 17.29% to $2.17. The market value of their outstanding shares is at $75.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Eagle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGRX#NASDAQ">EGRX</a>) shares decreased by 36.2% to $2.27 during Wednesday's regular session. The market value of their outstanding shares is at $29.4 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock decreased by 31.88% to $1.41. The company's market cap stands at $2.2 million. </li>
<li>Shattuck Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STTK#NASDAQ">STTK</a>) stock declined by 27.09% to $1.4. The company's market cap stands at $66.8 million. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) stock decreased by 19.76% to $0.35. The company's market cap stands at $7.2 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) shares decreased by 19.27% to $0.51. The market value of their outstanding shares is at $10.8 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) stock fell 17.8% to $1.71. The company's market cap stands at $3.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCAB

CLOV

IMAB

KLTO

MODV

RAPT

STTK

WINT

12 Health Care Stocks Moving In Wednesday's Intraday Session

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 100 points on Wednesday.
The Dow traded up 0.24% to 42,256.16 while the NASDAQ rose 0.27% to 17,958.08. The S&amp;P 500 also rose, gaining, 0.16% to 5,717.63.
Leading and Lagging Sectors Information technology shares jumped by 0.9% on Wednesday.
In trading on Wednesday, real estate shares dipped by 0.9%.
Top Headline
NIKE, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) reported mixed first-quarter results on Tuesday.
The company reported first-quarter revenue of $11.59 billion, missing analyst estimates of $11.65 billion. The athletic footwear and apparel company reported first-quarter earnings of 70 cents per share, beating analyst estimates of 52 cents per share.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Joby Aviation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) shares shot up 20% to $5.74 after the company announced that Toyota will invest an additional $500 million to support the certification and commercial production of the electric air taxi.</li>
<li>Shares of Great Lakes Dredge &amp; Dock Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLDD#NASDAQ">GLDD</a>) got a boost, surging 10% to $11.77 after the company announced the receipt of several dredging awards totaling $342.3 million.</li>
<li>MMTec, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTC#NASDAQ">MTC</a>) shares were also up, gaining 38% to $0.6480. Shares of US-listed Chinese stocks traded higher on continued strength following recent stimulus measures and the start of the National Day Golden Week.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) shares dropped 18% to $230.39 after the company provided update on decline in Stars performance for 2025 and how it will impact quality bonus payments in 2026.</li>
<li>Shares of Eagle Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGRX#NASDAQ">EGRX</a>) were down 36% to $2.28 after the company announced it will be delisted from the Nasdaq.</li>
<li>Aditxt Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) was down, falling 31% to $3.05. Aditxt recently announced a 1-for-40 reverse stock split.</li>
</ul>
Commodities In commodity news, oil traded up 0.6% to $70.22 while gold traded down 0.8% at $2,669.60.
Silver traded up 1% to $32.03 on Wednesday, while copper rose 1% to $4.6350.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.01%, Germany's DAX fell 0.38% and France's CAC 40 fell 0.09%. Spain's IBEX 35 Index fell 0.65%, while London's FTSE 100 gained 0.14%.
The unemployment rate in the Eurozone came in unchanged from the previous month at 6.4% in August.
Asia Pacific Markets
Asian markets closed mixed on Wednesday, with Japan's Nikkei 225 dipping 2.18% and Hong Kong's Hang Seng Index jumping 6.20%.
Economics
<ul>
<li>Private businesses in the U.S. added 143,000 workers to their payrolls during the month of September compared to a revised 103,000 gain in August and higher than market estimates of 124,000, the ADP said.</li>
<li>The EIA said crude oil inventories in the U.S. climbed by 3.889 million barrels for the week ended Sept. 27, versus market estimates of a 1.3 million decline.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41141190/nike-to-100-here-are-10-top-analyst-forecasts-for-wednesday">Nike To $100? Here Are 10 Top Analyst Forecasts For Wednesday</a></li>
</ul>

Intraday Update

GLDD

Dow Gains 100 Points; Joby Aviation Shares Spike Higher

U.S. stocks traded lower this morning, with the Dow Jones index falling around 0.1% on Wednesday.
Following the market opening Wednesday, the Dow traded down 0.07% to 42,127.56 while the NASDAQ fell 0.26% to 17,863.49. The S&amp;P 500 also fell, dropping, 0.18% to 5,698.62.
Leading and Lagging Sectors Energy shares jumped by 1.4% on Wednesday.
In trading on Wednesday, consumer discretionary shares dipped by 1.4%.
Top Headline
Private businesses in the U.S. added 143,000 workers to their payrolls during the month of September compared to a revised 103,000 gain in August and higher than market estimates of 124,000, the ADP said.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Kaixin Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KXIN#NASDAQ">KXIN</a>) shares shot up 130% to $0.2890 after dipping 35% on Tuesday.</li>
<li>Shares of Agora, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/API#NASDAQ">API</a>) got a boost, surging 95% to $5.36 after gaining 14% on Tuesday.</li>
<li>MMTec, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTC#NASDAQ">MTC</a>) shares were also up, gaining 62% to $0.7599. Shares of US-listed Chinese stocks traded higher on continued strength following recent stimulus measures and the start of the National Day Golden Week.</li>
</ul>
Equities Trading DOWN
<ul>
<li>American Rebel Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) shares dropped 43% to $4.30.</li>
<li>Shares of Eagle Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGRX#NASDAQ">EGRX</a>) were down 31% to $2.44 after the company announced it will be delisted from the Nasdaq.</li>
<li>Aditxt Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) was down, falling 36% to $2.85. Aditxt recently announced a 1-for-40 reverse stock split.</li>
</ul>
Commodities In commodity news, oil traded up 3.4% to $72.19 while gold traded down 0.5% at $2,676.10.
Silver traded up 1.4% to $32.18 on Wednesday, while copper rose 0.8% to $4.6260.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.3%, Germany's DAX fell 0.7% and France's CAC 40 fell 0.2%. Spain's IBEX 35 Index fell 0.7%, while London's FTSE 100 gained 0.2%.
The unemployment rate in the Eurozone came in unchanged from the previous month at 6.4% in August.
Asia Pacific Markets
Asian markets closed mixed on Wednesday, with Japan's Nikkei 225 dipping 2.18% and Hong Kong's Hang Seng Index jumping 6.20%.
Economics
Private businesses in the U.S. added 143,000 workers to their payrolls during the month of September compared to a revised 103,000 gain in August and higher than market estimates of 124,000, the ADP said.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41141190/nike-to-100-here-are-10-top-analyst-forecasts-for-wednesday">Nike To $100? Here Are 10 Top Analyst Forecasts For Wednesday</a></li>
</ul>

AREB

KXIN

US Stocks Edge Lower; Private Employment Beats Expectations

Eagle Pharmaceuticals Shares Resume Trade

Eagle Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Down -27.3%

WIIM

Eagle Pharmaceuticals shares are trading lower after the company announced it will be delisted from the Nasdaq.

Due to the matters described in Item 4.02 below, on October 1, 2024, Eagle Pharmaceuticals, Inc. (the "Company") notified the hearings panel (the "Panel") of The Nasdaq Stock Market LLC ("Nasdaq") that the Company did not anticipate filing its previously anticipated comprehensive Annual Report on Form 10-K for the period ended December 31, 2023, including restated financial information for the period ended June 30, 2023, financial information for the period ended September 30, 2023 and financial statements for the period ended December 31, 2023, a separate Quarterly Report on Form 10-Q for the period ended March 31, 2024, or a separate Quarterly Report on Form 10-Q for the period ended June 30, 2024 by the dates required to regain compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule").
&nbsp;
On October 1, 2024, the Company received a notice from the Panel stating that it had determined to delist the Company's common stock from Nasdaq and, effective at the open of business on October 3, 2024, to suspend trading of the Company's common stock on Nasdaq, as a result of the Company's failure to comply with the terms of the previously disclosed extension granted by the Panel to regain compliance with the Listing Rule. Nasdaq will complete the delisting by filing a Form 25 Notification of Delisting with the U.S. Securities and Exchange Commission ("SEC") after applicable appeal periods have lapsed, which will remove the Company's securities from listing and registration on Nasdaq. The Company has not requested that the Nasdaq Listing and Hearing Review Council review the Panel's decision.

Eagle Pharmaceuticals To Be Delisted From Nasdaq On October 3, 2024, Due To Non-Compliance; Trading Suspension And Delisting Filing With SEC After Appeal Period

The Company is working to prepare and file the Delayed Reports with the SEC&nbsp;by the applicable Compliance Dates to enable the Company to regain compliance with Nasdaq listing standards.

Eagle Pharmaceuticals Receives Delisting Notification From Nasdaq's Listing Qualifications Department

Legal

Eagle Pharmaceuticals TO Pay Curia $26.5M, With Payments Scheduled For $10M On July 5, 2024, Another $10M By February 17, 2025, And Final $6.5M By July 7, 2025; Filed Stipulation Of Discontinuance With Prejudice For NY Court Action

Eagle Pharmaceuticals shares are trading lower after the company announced a Nasdaq listing receipt.

<h3>Gainers</h3>
<ul>
<li>IGM Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGMS#NASDAQ">IGMS</a>) shares increased by 36.6% to $11.49 during Wednesday's regular session. The market value of their outstanding shares is at $678.1 million. </li>
<li>Akso Health Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) stock moved upwards by 21.96% to $1.05. The company's market cap stands at $153.8 million. </li>
<li>MultiPlan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLN#NYSE">MPLN</a>) shares rose 18.57% to $0.64. The company's market cap stands at $415.4 million. </li>
<li>Cyclerion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCN#NASDAQ">CYCN</a>) shares rose 14.61% to $2.98. The company's market cap stands at $7.4 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares increased by 12.79% to $1.41. The company's market cap stands at $9.3 million. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) shares moved upwards by 11.91% to $2.63. The market value of their outstanding shares is at $22.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares declined by 41.2% to $1.37 during Wednesday's regular session. The market value of their outstanding shares is at $7.6 million. </li>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) stock fell 36.85% to $1.92. The market value of their outstanding shares is at $8.6 million. </li>
<li>LifeStance Health Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFST#NASDAQ">LFST</a>) shares decreased by 19.42% to $6.03. The company's market cap stands at $2.3 billion. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) shares decreased by 17.1% to $0.26. The market value of their outstanding shares is at $3.2 million. </li>
<li>Eagle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGRX#NASDAQ">EGRX</a>) stock fell 16.71% to $3.64. The company's market cap stands at $47.1 million. </li>
<li>GT Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) stock decreased by 16.08% to $4.7. The company's market cap stands at $6.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDRX

CYCN

GTBP

IGMS

INDP

LFST

MBIO

MPLN

OGEN

RNAZ

Eagle Pharmaceuticals Announces Nasdaq Delisting Receipt

Eagle Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGRX#NASDAQ">EGRX</a>) ("Eagle" or the "Company") today announced&nbsp;that it will deliver a Trial in Progress presentation discussing the ongoing Phase 2/3 study of intravenous amisulpride as a prevention of postoperative nausea and vomiting (PONV) in pediatric patients from birth (full-term) until 17 years of age at the upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual Meeting, which is being held May 2-4, 2024, in Savannah, Georgia. &nbsp;
"Evaluating nausea in children remains a challenging and complex process," stated Mike Greenberg, MD, Vice President of Medical Affairs at Eagle Pharmaceuticals. "We are therefore pleased to have this opportunity to share the details of our ongoing Phase 2/3 study evaluating amisulpride to prevent postoperative nausea and vomiting in pediatric patients at this year's SAMBA 2024 Annual Meeting. Through this study, we hope to demonstrate the potential benefit of amisulpride therapy in this pediatric patient population, and we look forward to presenting preliminary results from this study in the second half of 2025."
Details of the presentations are as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Abstract&nbsp;Title:</td>
<td>Randomized, Double-Blind, Parallel-Group Active-Controlled Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients: Trial in Progress</td>
</tr>
<tr>
<td>Date:</td>
<td>Thursday, May 2, 2024</td>
</tr>
<tr>
<td>Times:</td>
<td>5:10-6:10pm</td>
</tr>
<tr>
<td>Presenter:</td>
<td>Dr. Lynn Bichajian</td>
</tr>
</tbody>
</table>
</figure>

Biotech

General

Eagle Pharmaceuticals Announces A Trial In Progress Presentation Of Phase 2/3 Study Of Intravenous Amisulpride As Prevention Of Postoperative Nausea And Vomiting In Pediatric Patients At The Upcoming Society For Ambulatory Anesthesia 2024 Annual Meeting

Health Care

Eagle Pharmaceuticals To Present Additional Data from Phase 3 Trial Showing Sustained Response of Amisulpride For Rescue Treatment of Postoperative Nausea and Vomiting At Upcoming ASPAN 2024 National Conference

Eagle Pharmaceuticals Announces Receipt Of Notification Of Deficiency From Nasdaq Regarding Requirement To Timely File Annual Report On Form 10-K

United States Court Of Appeals For The Federal Circuit Affirmed The Previously Announced Decision By The United States District Court For The District Of Delaware Finding That Drug Applications Referencing Eagle Pharmaceuticals&#39; Belrapzo (Bendamustine) Filed By Slayback Pharma And Apotex Did Not Infringe Eagle&#39;s Previously Issued &lsquo;483 Patent

Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio

-- BARHEMSYS&#xAE; (amisulpride) Injection is the first and only antiemetic approved by the U.S. Food and Drug Administration ("FDA") for rescue treatment of postoperative nausea and vomiting ("PONV") despite prophylaxis1 and is also approved for the treatment of PONV in patients who have not received prophylaxis and for the prevention of PONV --
-- In patients who experience PONV, the incidence of nausea is substantially greater than the incidence of vomiting2,3 --
-- This post-hoc analysis of pivotal trials demonstrates that Barhemsys provides statistically significant (p=0.006) nausea relief in patients with established PONV --
-- A single 10 mg dose of intravenous amisulpride significantly reduced patients' nausea across multiple measures, including significant nausea, use of rescue medication, and evolution of nausea over time, and the adverse event profile was comparable between the placebo and 10 mg amisulpride arms –
-- Unique J-code for Barhemsys (J-0184) from CMS effective on January 1, 2024 --
&nbsp;
WOODCLIFF LAKE, N.J., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGRX#NASDAQ">EGRX</a>) ("Eagle" or the "Company") today announced that its abstract, a post-hoc analysis of two multicenter, placebo-controlled, Phase III studies evaluating amisulpride (a selective dopamine D2/D3 antagonist) as an antiemetic in patients with established postoperative nausea and vomiting, has been selected for a poster presentation at the 77th PGA (PostGraduate Assembly in Anesthesiology), being held December 8-11, 2023, in New York City. The conference is sponsored by the New York State Society of Anesthesiologists and is a global platform for presenting anesthesia's latest science and technologies.
"PONV contributes to prolonged post-anesthesia care unit and hospital stays and is distressing to patients and healthcare providers," stated Mike Greenberg, MD, Vice President of Medical Affairs at Eagle Pharmaceuticals. "In patients who experience PONV, nausea occurs much more frequently than vomiting. This analysis details pooled data on nausea-related outcomes from two Phase III trials. We are pleased to share that the proportion of patients with PONV experiencing substantial nausea in these studies was statistically significantly lower in the amisulpride 10 mg group than in the placebo group. We believe Barhemsys presents an opportunity for a much-needed therapeutic option for these patients," concluded Dr. Greenberg.
Details of the poster presentation are as follows:
Abstract Title: <a href="https://www.globenewswire.com/Tracker?data=YvAl2q1zR_4Bz4Kd4_m1PD_EGGf5yxkGhTTdev2tDLwV5QeEsXyk-ursGiuCsnuI7BOyOdkhgoCuZ07r0x5B3PR1PnL_GNamI3ltMce9DrnDCS8vKwd6Bqoj7GDlrRq2vUL4aaOFNR03jNlU3GXH-mfYiYKxq9Fx5IUKuFoJxgtkGo2rx2Y-WokvcBtNeRIo9tmhIqgfZ2R8kHak66sJ3hbHBhIo27G4rCKZ13Gfk288IlZuvHRo0rdE-E1EaHjnA66bcoDTC7l7pwbkQu51pnYNS3OBXTejklbe4xUeAK9DWlc_D23QljeYn2VN3klw">Amisulpride Provides Significant Nausea Reduction in Patients with Established Postoperative Nausea and Vomiting: Pooled Results from Two Phase III Trials</a>
 &nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Date:</td>
<td>December 10, 2023</td>
</tr>
<tr>
<td>Time:</td>
<td>3:30pm ET</td>
</tr>
<tr>
<td>Location:</td>
<td>Room 4, Monitor 7</td>
</tr>
</tbody>
</table>
</figure>

Events

Eagle Pharmaceuticals To Present Abstract On Post-Hoc Analysis Of Amisulpride At The 77th PGA In New York City

<h3>Gainers</h3>
<ul>
<li>Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) shares increased by 45.2% to $4.59 during Thursday's after-market session. The company's market cap stands at $246.6 million. </li>
<li>NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) stock increased by 9.89% to $0.33. The market value of their outstanding shares is at $2.1 million. </li>
<li>China Pharma Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) shares rose 9.63% to $0.12. The market value of their outstanding shares is at $3.9 million. </li>
<li>NeuBase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBSE#NASDAQ">NBSE</a>) stock moved upwards by 9.48% to $1.08. The company's market cap stands at $4.0 million. </li>
<li>Minerva Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTRS#NASDAQ">UTRS</a>) stock increased by 8.1% to $2.0. The market value of their outstanding shares is at $17.7 million. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) stock increased by 7.95% to $0.53. The company's market cap stands at $2.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ampio Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AMPE#AMEX">AMPE</a>) shares declined by 20.5% to $4.58 during Thursday's after-market session. The market value of their outstanding shares is at $3.8 million. </li>
<li>Corbus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) stock declined by 9.23% to $6.0. The company's market cap stands at $26.5 million. </li>
<li>Eagle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGRX#NASDAQ">EGRX</a>) shares decreased by 8.55% to $5.35. The company's market cap stands at $69.4 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock declined by 8.49% to $1.51. The market value of their outstanding shares is at $14.3 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) stock decreased by 8.34% to $4.63. The market value of their outstanding shares is at $4.5 million. </li>
<li>LumiraDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMDX#NASDAQ">LMDX</a>) shares declined by 8.12% to $0.16. The company's market cap stands at $50.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKAN

AMPE

BIAF

CRBP

LMDX

NBSE

QNRX

UTRS

12 Health Care Stocks Moving In Thursday's After-Market Session

Press Releases

Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

Snowflake, Eagle Pharmaceuticals, Blue Ridge Bankshares, and Amplitude Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan

Management

Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer

Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration

Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan

Financing

Contracts

Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties

AMPL

BRBS

SNOW

Piper Sandler

Comments

Eagle Pharmaceuticals

Notizie

Ultime notizie per Eagle Pharmaceuticals (OTC:EGRX) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO